Literature DB >> 26308967

How many individuals will need to be screened to increase colorectal cancer screening prevalence to 80% by 2018?

Stacey A Fedewa1,2, Jiemin Ma1, Ann Goding Sauer1, Rebecca L Siegel1, Robert A Smith3, Richard C Wender3, Mary K Doroshenk3, Otis W Brawley4, Elizabeth M Ward1, Ahmedin Jemal1.   

Abstract

BACKGROUND: A recent study estimates that 277,000 colorectal cancer (CRC) cases and 203,000 CRC deaths will be averted between 2013 and 2030 if the National Colorectal Cancer Roundtable goal of increasing CRC screening prevalence to 80% by 2018 is reached. However, the number of individuals who need to be screened (NNS) to achieve this goal is unknown. In this communication, the authors estimate the NNS to achieve 80% by 2018 nationwide and by state.
METHODS: The authors estimated the NNS by subtracting adults aged 50 to 75 years who would need to be screened to achieve an 80% CRC screening prevalence from the number who are currently guideline-compliant from population estimates for this age group. The 2013 National Health Interview Survey and the 2012 Behavioral Risk Factor Surveillance System were used to estimate CRC screening prevalence and data from the US Census Bureau were used to estimate population projections. The NNS were age-standardized and sex-standardized.
RESULTS: Nationwide, 24.39 million individuals (95% confidence interval, 24.37-24.41 million) aged 50 to 75 years will need to be screened to achieve 80% by 2018. By state, the NNS ranged from 45,400 in Vermont to 2.72 million in California. The majority of individuals who need to be screened are aged 50 to 64 years and the largest subgroup is privately insured.
CONCLUSIONS: The authors estimated that at least 24.4 million additional individuals in the United States will need to be screened to achieve the National Colorectal Cancer Roundtable goal of increasing CRC screening prevalence to 80% by 2018. To reach this goal, improving facilitators of CRC screening, including physician recommendation and patient awareness, is needed.
© 2015 American Cancer Society.

Entities:  

Keywords:  National Colorectal Cancer Roundtable; cancer screening; colorectal neoplasms; public health; socioeconomic status

Mesh:

Year:  2015        PMID: 26308967     DOI: 10.1002/cncr.29659

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  Rectal cancer survival in the United States by race and stage, 2001 to 2009: Findings from the CONCORD-2 study.

Authors:  Djenaba A Joseph; Chris J Johnson; Arica White; Manxia Wu; Michel P Coleman
Journal:  Cancer       Date:  2017-12-15       Impact factor: 6.860

2.  Decrease in Incidence of Colorectal Cancer Among Individuals 50 Years or Older After Recommendations for Population-based Screening.

Authors:  Caitlin C Murphy; Robert S Sandler; Hanna K Sanoff; Y Claire Yang; Jennifer L Lund; John A Baron
Journal:  Clin Gastroenterol Hepatol       Date:  2016-09-05       Impact factor: 11.382

3.  The Association Between Primary Source of Healthcare Coverage and Colorectal Cancer Screening Among US Veterans.

Authors:  Folasade P May; Elizabeth M Yano; Dawn Provenzale; W Neil Steers; Donna L Washington
Journal:  Dig Dis Sci       Date:  2017-05-20       Impact factor: 3.199

4.  Time to fecal immunochemical test completion for colorectal cancer screening.

Authors:  Cameron B Haas; Amanda I Phipps; Anjum Hajat; Jessica Chubak; Karen J Wernli
Journal:  Am J Manag Care       Date:  2019-04       Impact factor: 2.229

5.  Colorectal cancer screening: Estimated future colonoscopy need and current volume and capacity.

Authors:  Djenaba A Joseph; Reinier G S Meester; Ann G Zauber; Diane L Manninen; Linda Winges; Fred B Dong; Brandy Peaker; Marjolein van Ballegooijen
Journal:  Cancer       Date:  2016-05-20       Impact factor: 6.860

6.  Colonoscopy vs. Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM): Rationale for Study Design.

Authors:  Jason A Dominitz; Douglas J Robertson; Dennis J Ahnen; James E Allison; Margaret Antonelli; Kathy D Boardman; Maria Ciarleglio; Barbara J Del Curto; Grant D Huang; Thomas F Imperiale; Meaghan F Larson; David Lieberman; Theresa O'Connor; Timothy J O'Leary; Peter Peduzzi; Dawn Provenzale; Aasma Shaukat; Shahnaz Sultan; Amy Voorhees; Robert Wallace; Peter D Guarino
Journal:  Am J Gastroenterol       Date:  2017-10-10       Impact factor: 10.864

7.  Downregulation of microRNA-30d promotes cell proliferation and invasion by targeting LRH-1 in colorectal carcinoma.

Authors:  Likun Yan; Jian Qiu; Jianfeng Yao
Journal:  Int J Mol Med       Date:  2017-04-20       Impact factor: 4.101

8.  Financial Incentives to Increase Colorectal Cancer Screening Uptake and Decrease Disparities: A Randomized Clinical Trial.

Authors:  Beverly B Green; Melissa L Anderson; Andrea J Cook; Jessica Chubak; Sharon Fuller; Kilian J Kimbel; Jeffrey T Kullgren; Richard T Meenan; Sally W Vernon
Journal:  JAMA Netw Open       Date:  2019-07-03

9.  LINC01638 silencing inhibits cancer cell proliferation in colorectal adenocarcinoma through interaction with RUNX2.

Authors:  Wenying Zhuo; Dengdi Hu; Xihua Chen; Tian Zhang
Journal:  Mol Med Rep       Date:  2019-04-25       Impact factor: 2.952

10.  Patterns and Trends in Cancer Screening in the United States.

Authors:  Ingrid J Hall; Florence K L Tangka; Susan A Sabatino; Trevor D Thompson; Barry I Graubard; Nancy Breen
Journal:  Prev Chronic Dis       Date:  2018-07-26       Impact factor: 2.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.